NasdaqGS - Delayed Quote USD
Amneal Pharmaceuticals, Inc. (AMRX)
7.41
-0.05
(-0.67%)
At close: May 9 at 4:00:01 PM EDT
7.25
-0.16
(-2.16%)
Pre-Market: 8:18:16 AM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 0.17 | 0.17 | 0.71 | 0.82 |
| Low Estimate | 0.16 | 0.17 | 0.69 | 0.78 |
| High Estimate | 0.18 | 0.18 | 0.73 | 0.85 |
| Year Ago EPS | 0.16 | 0.16 | 0.58 | 0.71 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 744.23M | 779.22M | 3.01B | 3.23B |
| Low Estimate | 740.09M | 776.37M | 3B | 3.13B |
| High Estimate | 750M | 783M | 3.02B | 3.3B |
| Year Ago Sales | 701.78M | 702.47M | 2.79B | 3.01B |
| Sales Growth (year/est) | 6.05% | 10.93% | 7.69% | 7.35% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | 0.14 | 0.14 | 0.15 | 0.15 |
| EPS Actual | 0.16 | 0.16 | 0.12 | 0.21 |
| Difference | 0.02 | 0.02 | -0.03 | 0.06 |
| Surprise % | 15.05% | 18.30% | -21.08% | 43.18% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0.17 | 0.17 | 0.71 | 0.82 |
| 7 Days Ago | 0.18 | 0.2 | 0.68 | 0.8 |
| 30 Days Ago | 0.18 | 0.2 | 0.68 | 0.8 |
| 60 Days Ago | 0.17 | 0.18 | 0.68 | 0.82 |
| 90 Days Ago | 0.18 | 0.18 | 0.75 | 0.8 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 2 | 1 |
| Up Last 30 Days | 1 | 1 | 2 | 1 |
| Down Last 7 Days | 2 | 2 | -- | 1 |
| Down Last 30 Days | 2 | 2 | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AMRX | 6.16% | 8.17% | 21.71% | 15.52% |
| S&P 500 | 13.21% | 3.06% | 8.01% | 13.77% |
Upgrades & Downgrades
| Maintains | Barclays: Overweight to Overweight | 3/3/2025 |
| Upgrade | JP Morgan: Neutral to Overweight | 2/24/2025 |
| Maintains | Piper Sandler: Overweight to Overweight | 11/11/2024 |
| Maintains | Truist Securities: Buy to Buy | 10/2/2024 |
| Upgrade | JP Morgan: Underweight to Neutral | 9/6/2024 |
| Maintains | Barclays: Overweight to Overweight | 8/13/2024 |
Related Tickers
LFCR Lifecore Biomedical, Inc.
6.97
+1.16%
ANIK Anika Therapeutics, Inc.
11.64
-21.03%
KMDA Kamada Ltd.
6.88
-1.57%
RDY Dr. Reddy's Laboratories Limited
13.40
+1.67%
OPTN OptiNose, Inc.
9.39
0.00%
ALKS Alkermes plc
30.13
-0.82%
AMPH Amphastar Pharmaceuticals, Inc.
24.11
-2.19%
HLN Haleon plc
10.74
+1.61%
ALVO Alvotech
9.68
+3.20%
AQST Aquestive Therapeutics, Inc.
2.7900
+1.09%